Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Repair Biotechnologies Announces Appointment of Noted Endocrinologist Prof. Frederick J. Raal to Scientific Advisory Board

SYRACUSE, NY / ACCESS Newswire / October 16, 2025 / Repair Biotechnologies, Inc. (https://www.repairbiotechnologies.com/), a biotechnology company developing first-in-class therapies capable of rapidly reducing and stabilizing atherosclerotic plaque, today announced the appointment of Prof. Frederick J. Raal as a scientific advisor.

"We are pleased to welcome Prof. Frederick J. Raal, a noted endocrinologist and specialist in the study and treatment of familial hypercholesterolemia, to our Scientific Advisory Board," said Reason, Chief Executive Officer and Co-Founder of Repair Biotechnologies. "His extensive clinical expertise with lipid disorders such as homozygous familial hypercholesterolemia, our initial clinical indication, will be critical in advancing our novel approach to the treatment of patients exhibiting severe progression of atherosclerosis and risk of mortality. In preclinical models, our candidate drug produces a rapid and sizable regression and stabilization of the dangerous arterial plaque that is the cause of heart attack and stroke. If carried through into the clinic, this would represent a considerable advance over the present standard of care."

Prof. Raal states, "Familial hypercholesterolemia, particularly the homozygous form, remains a difficult condition to treat. Although therapies have advanced, safe and reliable regression and stabilization of the atherosclerotic plaque that causes premature morbidity and mortality in these patients is an important goal to pursue. Novel therapies are much needed by patients and physicians to reduce the burden of atherosclerosis and prolong the lives of those living with familial hypercholesterolemia."

Prof. Frederick J. Raal, MMED, PhD, DSC, is a Distinguished Professor in the Division of Endocrinology and Metabolism, as well as Director of the Carbohydrate and Lipid Metabolism Research Unit, University of the Witwatersrand, Johannesburg, South Africa. He is a NRF A-rated scientist and has authored or co-authored over 400 original articles and book chapters and has reviewed for several international journals including the New England Journal of Medicine, the Lancet, Circulation, and Atherosclerosis. He is on the Editorial Board of Atherosclerosis and a co-editor for Current Opinion in Lipidology. Professor Raal is particularly interested in lipids and lipid disorders and has been integrally involved in the management of familial dyslipidemia, particularly heterozygous and homozygous familial hypercholesterolemia (FH). The major focus of his research remains the clinical, biochemical, genetic and therapeutic management of this condition and he continues to conduct studies with novel therapies such as PCSK9-inhibitors and ANGPTL3-inhibitors in this patient group.

Contact Information

Reason.
CEO and Co-Founder
press@repairbiotechnologies.com
+1 315-299-2407


.

SOURCE: Repair Biotechnologies, Inc.



View the original press release on ACCESS Newswire

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.